Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $1.9 million.

  • Immunocore Holdings' Cash from Financing Activities rose 842.42% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year decrease of 110.81%. This contributed to the annual value of $343.9 million for FY2024, which is 901.23% up from last year.
  • Per Immunocore Holdings' latest filing, its Cash from Financing Activities stood at $1.9 million for Q3 2025, which was down 49.16% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Cash from Financing Activities ranged from a high of $396.0 million in Q1 2024 and a low of -$51.5 million during Q4 2024.
  • Its 3-year average for Cash from Financing Activities is $35.1 million, with a median of $3.7 million in 2025.
  • Examining YoY changes over the last 5 years, Immunocore Holdings' Cash from Financing Activities showed a top increase of 6,350.76% in 2024 and a maximum decrease of 923.65% in 2024.
  • Over the past 3 years, Immunocore Holdings' Cash from Financing Activities (Quarterly) stood at $6.3 million in 2023, then tumbled by 923.65% to -$51.5 million in 2024, then skyrocketed by 842.42% to $1.9 million in 2025.
  • Its Cash from Financing Activities stands at $1.9 million for Q3 2025, versus $3.7 million for Q2 2025 and $2.6 million for Q1 2025.